$1.48
-0.34%
2026-09-04 10:04:07 EDT-$0.00
보건의료
생명공학
NASDAQ
활발히 거래 중
Aldeyra Therapeutics, Inc.는 생명공학 기업으로서 면역 매개 질환을 치료하도록 설계된 치료제를 발견하고 개발합니다. 주요 파이프라인 후보 물질은 반응성 알데하이드 종(RASP) 조절제인 reproxalap이며, ...
Aldeyra Therapeutics, Inc.는 생명공학 기업으로서 면역 매개 질환을 치료하도록 설계된 치료제를 발견하고 개발합니다. 주요 파이프라인 후보 물질은 반응성 알데하이드 종(RASP) 조절제인 reproxalap이며, ...
C-레벨 임원은 회사의 재무 전략과 혁신을 이끄는 응집된 리더십 팀입니다.
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
| Todd C. Brady | 최고경영자, 사장 겸 이사 | USD 903,000 | — | 1972 | Active |
| Michael Alfieri | 재무 담당 책임자 및 주요 재무·회계 책임자 | USD 243,994 | 1965 | Active | |
| Laura Nichols | 운영 관리자 | — | — | — | Active |
| Adam Lazorchak | 번역과학 책임자 및 비임상 개발 책임자 | — | — | — | Active |
| David Burke | 투자자 관계 책임자 | — | — | — | Active |
| Filing Date | Year | Name | Position | Level | Salary | Bonus | Stock Award | Option Award | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | 2025 | Todd C. Brady, M.D., Ph.D. | President President and Chief Chief Executive Officer | Founder / CEO | $700.00K | $0 | $0 | $3.80M | $189.00K | $14.00K | $4.70M |
| 2026-04-27 | 2025 | Stephen G. Machatha, Ph.D. | Chief Chief Development Officer | C-Level | $400.00K | $0 | $0 | $950.34K | $0 | $101.80K | $1.45M |
| 2026-04-27 | 2025 | Michael Alfieri | Principal Principal Financial Officer and Principal Principal Accounting Officer | Other | $0 | $0 | $0 | $0 | $0 | $243.99K | $245.96K |
| 2026-04-27 | 2024 | Todd C. Brady, M.D., Ph.D. | President President and Chief Chief Executive Officer | Founder / CEO | $591.63K | $0 | $0 | $3.00M | $325.40K | $13.80K | $3.93M |
| 2026-04-27 | 2024 | Stephen G. Machatha, Ph.D. | Chief Chief Development Officer | C-Level | $392.34K | $0 | $0 | $1.13M | $156.94K | $13.80K | $1.69M |
| 2026-04-27 | 2024 | Michael Alfieri | Principal Principal Financial Officer and Principal Principal Accounting Officer | Other | $0 | $0 | $0 | $0 | $0 | $111.65K | $111.65K |
Sum of disclosed compensation by year (USD million)
Top founder/C-level executives over time (USD million)